A detailed history of Virtu Financial LLC transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 58,791 shares of MCRB stock, worth $56,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,791
Previous 40,600 44.81%
Holding current value
$56,439
Previous $29,000 93.1%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 20, 2024

BUY
$0.7 - $1.48 $12,733 - $26,922
18,191 Added 44.81%
58,791 $56,000
Q2 2024

Aug 09, 2024

SELL
$0.56 - $1.19 $30,189 - $64,152
-53,910 Reduced 57.04%
40,600 $29,000
Q1 2024

May 20, 2024

BUY
$0.75 - $1.56 $70,882 - $147,435
94,510 New
94,510 $73,000
Q1 2022

May 17, 2022

SELL
$6.3 - $8.84 $216,858 - $304,290
-34,422 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$6.02 - $11.43 $207,220 - $393,443
34,422 New
34,422 $287,000
Q2 2021

Sep 17, 2021

SELL
$18.46 - $24.36 $430,930 - $568,659
-23,344 Closed
0 $0
Q1 2021

May 19, 2021

BUY
$17.66 - $28.92 $412,255 - $675,108
23,344 New
23,344 $481,000
Q2 2020

Aug 07, 2020

SELL
$3.04 - $6.2 $34,075 - $69,495
-11,209 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$2.99 - $4.42 $33,514 - $49,543
11,209 New
11,209 $39,000
Q3 2019

Nov 20, 2019

SELL
$2.29 - $4.16 $33,727 - $61,268
-14,728 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$2.28 - $7.35 $9,286 - $29,936
4,073 Added 38.23%
14,728 $47,000
Q1 2018

May 14, 2018

BUY
$7.34 - $11.16 $78,207 - $118,909
10,655 New
10,655 $78,000
Q4 2017

Feb 09, 2018

SELL
$9.15 - $12.64 $141,623 - $195,641
-15,478 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$12.81 - $16.85 $198,273 - $260,804
15,478
15,478 $0

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $119M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.